Table IX.
Pathway names that are identified by Bayesian inference based on the Bayes factor larger than 150 by using the four kernels but that are not detected from global test, GSEA, and resampling-based methods.
| Pathway ID | Name | No. of genes |
|---|---|---|
| 44 | c23_U133_probes (user defined) | 67 |
| 213 | MAPK signaling pathway | 274 |
| 107 | Inositol phosphate metabolism | 52 |
| 50 | c29_U133_probes (user defined) | 119 |
| 38 | c19_U133_probes (user defined) | 174 |
| 94 | Glycerolipid metabolism | 96 |
| 221 | N-Glycans biosynthesis | 38 |
| 41 | c21_U133_probes (user defined) | 191 |
| 34 | c15_U133_probes (user defined) | 154 |
| 138 | MAP00240_Pyrimidine_metabolism (user defined) | 45 |
| 54 | c32_U133_probes (user defined) | 203 |
| 96 | GLYCOGEN_HG-133A_probes (user defined) | 26 |
| 155 | MAP00380_Tryptophan_metabolism (user defined) | 60 |
| 246 | Purine metabolism | 112 |
| 186 | MAP00620_Pyruvate_metabolism (user defined) | 49 |
| 47 | c26_U133_probes (user defined) | 220 |
| 148 | MAP00310_Lysine_degradation (user defined) | 24 |
| 75 | Dentatorubropallidoluysian atrophy (DRPLA) | 23 |
| 115 | Lysine degradation | 44 |
| 67 | Cholera - Infection | 72 |
| 219 | Neurodegenerative disorders | 33 |
| 70 | Citrate cycle (TCA cycle) | 39 |
| 248 | Pyrimidine metabolism | 61 |
| 259 | Starch and sucrose metabolism | 54 |
| 257 | Sphingoglycolipid metabolism | 55 |
| 105 | Huntington’s disease | 46 |
| 71 | Complement and coagulation cascades | 47 |
| 82 | Fatty acid metabolism | 79 |
| 238 | Phosphatidylinositol signaling system | 58 |